While blockade of ICOS signals continues to be investigated in experimental and pre-clinical models, as mentioned above blockade of the CD28 pathway has reached clinical application in that the CTLA-4 Ig fusion proteins abatacept and belatacept are currently approved for use in autoimmunity and transplantation, respectively. Here, ICOS is linked to Autoimmunity.